Allogene Therapeutics is set to undergo leadership changes as CEO David Chang announces his departure. This transition comes at a time of notable activity in the biotech sector.
Pfizer has recently made headlines with its substantial investment aimed at acquiring Chinese pharmaceutical companies, indicating a strategic expansion into that market.
Additionally, the World Health Organization is mapping out an experimental response to the ongoing Ebola outbreak, highlighting the urgent need for effective interventions in global health crises.